“…Inhibition of HDACs has been shown to abolish drug-resistance in cancer cells (36). In support of this finding, HDAC inhibition sensitizes neuroblastoma cells to the genotoxins etoposide, melphalan, carboplatin and vincristine (37), melanoma cells to temozolomide, psoralen and UVA, fotemustine and ionizing radiation (16,38,39), prostate cancer cells to bleomycin, doxorubicin, etoposide, hydroxyurea, cisplatin and ionizing radiation (40,41), breast cancer cells to etoposide and olaparib (42,43) and head and neck cancer cells to cisplatin (44). In addition, HDAC inhibition sensitizes squamous cell carcinoma, non-small cell lung cancer, osteosarcoma, rhabdomyosarcoma and cervical cancer cells to ionizing radiation (45–48).…”